<DOC>
	<DOCNO>NCT00440258</DOCNO>
	<brief_summary>The present study design provide clinical confirmation Cb2 ’ value new approach prevention increase vascular permeability hemoconcentration , sign OHSS human , order explore mechanism action . To end , prospective , randomize , placebo-controlled study design Cb2 employ woman risk OHSS gonadotropin administration ART . Simultaneously , ovarian perfusion assess patient use MR pharmacokinetic modeling .</brief_summary>
	<brief_title>Cabergoline Reduces OHSS</brief_title>
	<detailed_description>Patients Study design This study perform 82 oocyte donor April 2004 July 2006 . The study protocol approve institution ’ Ethical Committee participant sign write consent form . The protocol COH previously describe ( 23 ) . Only patient risk develop OHSS include . The definition risk development 20-30 follicle &gt; 12 mm diameter , retrieval &gt; 20 oocyte . Once decision administer hCG take , patient immediately allocate two group base computer randomization : study group initially consist 41 patient , 6 discard randomization &lt; 20 oocyte retrieve despite development &gt; 20 follicle &gt; 12 mm . Thus , remain total 35 patient receive one 0.5 mg tablet Cb2 daily eight day . The control group also initially compose 41 woman . However , 7 meet criterion number oocytes retrieve , 2 donor decide withdraw study . This leave remain total 32 woman , complete study , receive placebo tablet daily 8 day . Women monitor every 48 hour day hCG ( day 0 ) day 8 . On day hCG+4 , order define ascites , provide certain degree fluid pouch Douglas ovum pick-up , employed transvaginal ultrasound ( TVU ) measure two major perpendicular diameter fluid pocket 15 donor show risk OHSS . We observe 3.5±2.8 cm2 fluid pelvis normal condition . Therefore , existence ascites confirm pocket peritoneal fluid &gt; 9 cm2 observe patient lithotomy position ( gynecological table always 45º floor room ) , result mean± 2 standard deviation ( SD ) value find non-OHSS candidate . TVU scan perform researcher ( CA ) , blind treatment patient submit . A 6.5 MHz vaginal probe ( Voluson 730 Pro V , General Electric , Madrid , Spain ) employ TVU scan . To evaluate biochemical risk hemoconcentration , evaluate hemoglobin , hematocrit , leukocyte count . Moreover , renal ( creatinine ) liver [ transaminase : aspartate aminotransferase ( AST ) ; alanine aminotransferase ( ALT ) ] function , electrolyte ( Na , K ) analyze ascertain severity syndrome . Since woman undergo ART experience certain degree discomfort enlarge ovary ( know mild OHSS ) , center attention analyze incidence moderate severe OHSS , identify accord modify ( 24 ) classification Golan et al ( 25 ) . Moderate OHSS confirm patient present ultrasonographic evidence ascites , diagnosis severe OHSS require clinical evidence ascites and/or hydrothorax breathing difficulty , one follow criterion : ) increase blood viscosity due hemoconcentration ( hemoglobin ≥15 g/dl , hematocrit ≥45 % , leukocyte count ≥20,000/mm3 ) ; b ) coagulation abnormality ; c ) diminish renal perfusion function ( serum creatinine level &gt; 1.2 mg/dl ) ; ) liver dysfunction : define transaminase ( AST ALT ) &gt; 40 U/ml ( 24 , 25 ) . Additionally , serum PRL level measure adverse drug reaction record . An end-of-study assessment schedule 7-10 day last dose Cb2/placebo . Moreover , first 8 patient include study , follicular fluid aspirate without obvious blood contamination collect , pool mRNA extract quantify amount Dp-r2 human ovary , employ two different molecular technique . To objectively analyze change vascular permeability fluid shift , confirmatory study perform six woman study group four control , employ magnetic resonance ( MR ) describe . Dynamic contrast-enhanced MR perform three different stage study : baseline , gonadotropin administration initiate ; hCG injection ; day hCG+5 , oocyte pick-up .</detailed_description>
	<mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Cabergoline</mesh_term>
	<mesh_term>Dopamine Agonists</mesh_term>
	<criteria>18 35 year old healthy woman , risk develop OHSS . No risk develop OHSS ; &lt; 20 oocyte retrieve .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Ovarian hyperstimulation syndrome , dopamine agonist , cabergoline , hemoconcentration , ascites , ovarian perfusion , dopamine receptor 2</keyword>
</DOC>